Teradyne Reports Third Quarter 2026 Results

Teradyne reported Q3 2026 revenue of $1.306 billion, up from $769 million in Q3 2025 but slightly below Q2 2026 revenue of $1.329 billion. GAAP EPS was $2.17, versus $0.75 a year earlier and $2.38 in the prior quarter; non-GAAP EPS was $2.29, compared with $0.85 and $2.47, respectively. Semiconductor Test contributed $1.072 billion of revenue, Product Test $138 million, and Robotics $96 million.

Analysis

The key signal is the sequential deceleration: revenue and EPS eased from Q2, despite the much stronger year-over-year comparison. That makes the result less clearly bullish than the growth headline suggests and raises the near-term question of whether semiconductor-test demand is still accelerating or entering a digestion phase. Semiconductor Test is the dominant earnings driver by revenue; Product Test and Robotics are too small, on the figures provided, to offset a slowdown there. The second-order exposure is customer capex: any pause in leading-edge and AI-related chip investment could flow quickly into test-equipment orders, while a sustained ramp would support utilization and follow-on demand. Advantest is the relevant competitive read-through, but the excerpt provides no relative order, share, or margin data to establish a winner. The report excerpt omits guidance, bookings, and management commentary, so it cannot establish whether the sequential easing was expected or whether forward demand weakened. Over the next 1–3 months, guidance and order trends matter more than the year-over-year growth rate; over 6–18 months, the thesis depends on continued semiconductor investment and Teradyne defending its position. A move that prices in uninterrupted acceleration is vulnerable to a capex pause; conversely, sequential stabilization alongside firm forward commentary would falsify the digestion concern.

Key Decisions for Investors

• Do not chase TER solely on the year-over-year comparison. Before adding, verify the full release and call for Q4 guidance, bookings or order commentary, and Semiconductor Test demand trends; these are missing from the excerpt.
• For the next 1–3 months, keep TER exposure neutral pending that verification. If the stock rallies while forward guidance or orders weaken, consider reducing exposure rather than assuming the reported growth rate will persist.
• Set an upside trigger for reassessment: sequential stabilization or improvement in Semiconductor Test, supported by forward guidance, would weaken the digestion thesis. A further sequential decline or a cut to forward expectations would strengthen it.
• Monitor Advantest commentary as a competitive and industry cross-check, not as a presumed direct hedge: the available data do not establish comparable product mix, valuation, or relative demand.